02348.HK
Dawnrays Pharmaceutical (Holdings) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.92
−1.60%Year over year
Reported trailing growth
- Revenue
- +2.3%
- EBITDA
- +42.3%
- EBIT
- +42.0%
- EPS
- +30.1%
- Free cash flow
- +52.2%
- Operating cash flow
- +50.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -1.2%
- EBITDA
- -11.7%
- EBIT
- -18.4%
- Net income
- -15.8%
- EPS
- -16.4%
- Free cash flow
- +0.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026